awmsg logo



cabozantinib (Cometriq®)


Reference No. 577

Publication date:
29/01/2015


Appraisal information

cabozantinib (Cometriq®) 20 mg capsule
cabozantinib (Cometriq®) 80 mg capsule


Company: Swedish Orphan Biovitrum Ltd/TMC Pharma Services Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 19/11/2014
AWMSG meeting date: 17/12/2014
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 4014
Ministerial ratification: 28/01/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Cabozantinib (Cometriq®) is recommended as an option for use within NHS Wales for the treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma. For patients in whom Rearranged during Transfection (RET) mutation status is not known or is negative, a possible lower benefit should be taken into account before individual treatment decision.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download